Abstract
We report a 74-year-old woman with primary CD5-positive diffuse large B-cell lymphoma (DLBCL) of the temporal bone. The patient was admitted because of a mass in the left external auditory canal. She was treated with eight courses of CEOP therapy (rituximab was added from the sixth course) followed by radiotherapy of 40 Gy, and complete remission was achieved. The occurrence of malignant lymphoma in the temporal bone, which is an extremely unusual site, may have depended on the peculiarity of CD5-positive DLBCL.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B-Lymphocytes / pathology
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / immunology
-
Bone Neoplasms / pathology*
-
CD5 Antigens*
-
Cyclophosphamide / administration & dosage
-
Ear Canal*
-
Ear Neoplasms / drug therapy
-
Ear Neoplasms / immunology
-
Ear Neoplasms / pathology*
-
Epirubicin / administration & dosage
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / immunology
-
Lymphoma, Large B-Cell, Diffuse / pathology*
-
Prednisone / administration & dosage
-
Rituximab
-
Temporal Bone*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
CD5 Antigens
-
Epirubicin
-
Rituximab
-
Vincristine
-
Cyclophosphamide
-
Prednisone